Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.

Authors
  • 1
  • 1 Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Type
Published Article
Journal
Journal of Clinical Oncology
1527-7755
Publisher
American Society of Clinical Oncology
Publication Date
Volume
28
Issue
13
Pages
2220–2226
Identifiers
DOI: 10.1200/JCO.2009.26.7765
PMID: 20351325
Source
Medline
License
Unknown

Abstract

Pegylated ADI is a promising drug that capitalizes on a significant enzymatic deficiency in HCC. It is safe, well tolerated, and may benefit patients with unresectable HCC.

Statistics

Seen <100 times